의약품 안전성 시장 : 제품 유형별, 서비스 유형별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Drug Safety Market is projected to grow by USD 10.21 billion at a CAGR of 5.99% by 2032.

Drug safety has become a board-level priority as pharmaceutical pipelines expand, therapies become more targeted, and post-market evidence grows across electronic health records, claims databases, registries, scientific literature, social and digital channels, and spontaneous reporting systems.

Global pharmacovigilance is anchored by established sources such as FDA FAERS, EMA EudraVigilance, the FDA Sentinel System, and WHO-UMC VigiBase, which contains more than 35 million individual case safety reports from over 150 countries. The drug safety landscape is moving toward faster adverse event detection, stronger benefit-risk management, and compliant automation across the full product lifecycle.

Transformative Shifts Reshaping Pharmacovigilance

The drug safety landscape is shifting from reactive adverse event processing to proactive, evidence-led pharmacovigilance. Regulators are emphasizing risk management plans, periodic safety update reports, real-world evidence, patient engagement, and data transparency across clinical development and commercialization.

Operationally, organizations are replacing fragmented safety workflows with integrated case intake, medical review, literature monitoring, aggregate reporting, signal detection, and risk management. Adoption of ICH E2B(R3), MedDRA coding, standardized quality systems, and cloud-based safety platforms is improving consistency while raising expectations for auditability, inspection readiness, and global pharmacovigilance harmonization.

Cumulative Impact of Artificial Intelligence on Drug Safety

Artificial intelligence is becoming a cumulative force in drug safety by accelerating duplicate detection, adverse event extraction, case validity assessment, narrative generation, MedDRA coding assistance, literature screening, and disproportionality analysis. These capabilities are most valuable when combined with human medical judgment, validated workflows, and documented quality controls.

Regulators have not removed accountability from marketing authorization holders; instead, they expect traceability, model governance, bias management, cybersecurity, data privacy safeguards, and documented performance monitoring. As AI matures, competitive advantage in pharmacovigilance will come from compliant augmentation rather than fully autonomous safety decision-making.

Key Regional Insights Across Global Drug Safety

North America remains a high-maturity drug safety region due to FDA FAERS, the FDA Sentinel System, Health Canada vigilance programs, strong inspection activity, and deep adoption of real-world evidence. Europe is similarly advanced, with EMA EudraVigilance, EU Good Pharmacovigilance Practices, and the Clinical Trials Regulation reinforcing centralized reporting, risk management, and benefit-risk oversight across member states.

Asia-Pacific is expanding its pharmacovigilance capabilities as China, India, Japan, South Korea, and Australia strengthen local safety reporting requirements, medical product monitoring, and digital health infrastructure. Latin America is improving drug safety capacity through national regulatory agencies, regional collaboration, and gradual modernization of adverse event reporting systems. The Middle East is advancing centralized safety oversight through health digitization and national pharmacovigilance programs, while Africa continues to build structured reporting capacity through national authorities, regional initiatives, and WHO-supported safety monitoring networks.

Key Group Insights for Regulatory and Market Alignment

The European Union provides one of the most harmonized pharmacovigilance environments, supported by EudraVigilance, EU GVP modules, coordinated benefit-risk reviews, and shared regulatory procedures. G7 markets remain influential benchmarks for multinational drug safety operations because they combine advanced analytics, inspection rigor, real-world evidence infrastructure, mature healthcare data systems, and patient safety governance.

ASEAN is progressing through regulatory convergence, capacity building, and stronger national adverse event reporting systems, while the GCC is investing in health digitization, national safety databases, and centralized oversight. BRICS markets are strategically important because China, India, Brazil, Russia, and South Africa combine large patient populations with evolving regulatory expectations and growing pharmacovigilance infrastructure. NATO markets overlap heavily with mature pharmacovigilance systems, emphasizing resilience, supply continuity, medical product safety readiness, and coordinated health security priorities.

Key Country Insights for Drug Safety Strategy

The United States leads in active safety surveillance through FDA FAERS, Sentinel, REMS programs, and mature real-world data use. Canada emphasizes post-market surveillance through Health Canada, while Mexico and Brazil continue strengthening national reporting and regulatory modernization. The United Kingdom maintains MHRA-led vigilance, and Germany, France, Italy, and Spain operate within the EU pharmacovigilance framework with strong national competent authorities and established pharmacovigilance centers.

Russia remains a significant Eurasian market with local reporting obligations and national pharmacovigilance requirements, while China, India, Japan, South Korea, and Australia are central to Asia-Pacific drug safety strategy. China and India offer large-scale patient exposure and rising regulatory sophistication; Japan and South Korea are highly structured markets with rigorous safety expectations; and Australia provides strong pharmacovigilance alignment through the Therapeutic Goods Administration and established post-market monitoring practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize globally harmonized safety operating models that align case processing, signal management, aggregate reporting, risk management, and quality assurance with ICH, FDA, EMA, and local requirements. Investment should focus on validated automation, interoperable safety databases, high-quality medical review, structured data standards, and robust vendor oversight.

Organizations should also build real-world evidence capabilities, strengthen patient-centric adverse event intake, and formalize AI governance across model validation, human review, audit trails, and cybersecurity. The most resilient drug safety functions will combine scientific expertise, regulatory intelligence, data stewardship, and continuous inspection readiness to reduce compliance risk while improving patient outcomes.

Research Methodology and Data Foundation

This executive summary is developed from verified public regulatory sources, international pharmacovigilance standards, and recognized safety data ecosystems, including FDA, EMA, WHO-UMC, ICH, national competent authorities, and published guidance on pharmacovigilance quality systems, adverse event reporting, and benefit-risk management.

The methodology emphasizes triangulation across regulatory frameworks, adverse event reporting infrastructure, regional policy direction, inspection expectations, technology adoption patterns, and recognized real-world evidence practices. Insights are synthesized to support decision-making while maintaining factual accuracy, market relevance, and compliance-oriented interpretation.

Conclusion: The Future of Drug Safety

Drug safety is entering a more connected, data-intensive, and accountability-driven era. The strategic focus is expanding beyond compliance to continuous benefit-risk optimization, faster signal detection, improved adverse event management, and responsible use of automation across the medicine lifecycle.

Organizations that modernize pharmacovigilance with validated AI, real-world evidence, global regulatory intelligence, standardized data governance, and human medical oversight will be best positioned to protect patients, satisfy regulators, and compete in an increasingly complex healthcare environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Safety Market, by Product Type

• 7.1. Labeling Management
• 7.2. Pharmacovigilance Systems
• 7.3. Regulatory Submission Management
• 7.4. Risk Management Modules
  • 7.4.1. Risk Evaluation Tools
  • 7.4.2. Risk Minimization Tools

8. Drug Safety Market, by Service Type

• 8.1. Consulting And Advisory
  • 8.1.1. Process Optimization Consulting
  • 8.1.2. Regulatory Compliance Consulting
• 8.2. Implementation And Integration
  • 8.2.1. Customization Services
  • 8.2.2. System Integration
• 8.3. Outsourcing
  • 8.3.1. Case Processing Outsourcing
  • 8.3.2. Pharmacovigilance Outsourcing
• 8.4. Training And Support
  • 8.4.1. End User Training
  • 8.4.2. Technical Support Services

9. Drug Safety Market, by Application

• 9.1. Adverse Event Reporting
• 9.2. Regulatory Compliance
• 9.3. Risk Evaluation
• 9.4. Safety Data Management
  • 9.4.1. Data Collection
  • 9.4.2. Data Processing
• 9.5. Signal Detection

10. Drug Safety Market, by End User

• 10.1. Biotechnology Companies
• 10.2. Contract Research Organizations
• 10.3. Hospitals And Clinics
• 10.4. Pharmaceutical Companies
• 10.5. Regulatory Authorities

11. Drug Safety Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Drug Safety Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Drug Safety Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 3B Pharmaceuticals GmbH
• 15.2. Accenture plc
• 15.3. ArisGlobal LLC
• 15.4. BioClinica, Inc.
• 15.5. Biosphere Clinical Research Private Limited
• 15.6. Charles River Laboratories International, Inc.
• 15.7. Cognizant Technology Solutions Corporation
• 15.8. Continuum Clinical Research India Private Limited
• 15.9. Ethicare Clinical Trial Services Private Limited
• 15.10. ICON plc
• 15.11. Indegene Limited
• 15.12. IQVIA Inc.
• 15.13. Laboratory Corporation of America Holdings
• 15.14. Lambda Therapeutic Research Limited
• 15.15. Linical Co., Ltd.
• 15.16. Medpace Holdings, Inc.
• 15.17. Oracle Corporation
• 15.18. Parexel International Corporation
• 15.19. PharmaLex GmbH
• 15.20. PrimeVigilance Ltd.
• 15.21. ProPharma Group
• 15.22. SIRO Clinpharm Private Limited
• 15.23. Syneos Health, Inc.
• 15.24. Tata Consultancy Services Limited
• 15.25. Veeda Clinical Research Limited
• 15.26. Veeva Systems Inc.
• 15.27. WuXi AppTec Co., Ltd.